Related Experiment Video
Updated: Mar 15, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Testicular germ cell tumor genomics
Solomon L Woldu1, James F Amatruda, Aditya Bagrodia
1University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
Purpose Of Review:
Testicular germ cell tumors (TGCTs) are a model for curable cancer because of exquisite chemosensitivity and incorporation of multimodal therapy. Nevertheless, our ability to predict metastases in early-stage disease and responders to chemotherapy in advanced disease is limited. Treatment options for cisplatin-resistant disease are sparse. A further understanding of TGCT biology may allow for more precise patient counseling and identify novel therapies in patients with cisplatin-resistant disease.
Recent Findings:
Adult TGCTs are characterized by frequent chromosomal anomalies and low rates of somatic mutations. Large-scale integrated molecular analysis of early-stage TGCT patients is actively underway. In addition to ubiquitous gain of isochromosome 12p, current molecular studies have confirmed mutations of previously described genes (i.e., KIT and KRAS) and described novel mutations. Analysis of cisplatin-resistant cases has identified high rates of alterations within the TP53-MDM2 axis and a high proportion of patients with potentially actionable targets, including TP53-MDM2, PI3 kinase, and MAPK signaling pathway alterations. The role of epigenetics in TGCT development and prognosis is also being further characterized.
Summary:
Further molecular characterization of TGCT may allow for avoidance of unnecessary treatment in patients with early-stage disease and also provide new treatment options in patients with cisplatin-resistant disease.
Insights
Understanding testicular germ cell tumor (TGCT) biology improves early-stage metastasis prediction and identifies new treatments for cisplatin-resistant disease. Further molecular analysis offers tailored therapies and better patient outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Testicular germ cell tumors (TGCTs) are highly curable but predicting early-stage metastasis and chemotherapy response remains challenging.
- Cisplatin-resistant TGCTs have limited treatment options, highlighting the need for novel therapeutic strategies.
- Understanding TGCT biology is crucial for improved patient counseling and developing targeted therapies.
Purpose of the Study:
- To review recent molecular findings in TGCT.
- To identify potential therapeutic targets in cisplatin-resistant TGCT.
- To explore how advanced molecular characterization can refine treatment strategies.
Main Methods:
- Review of integrated molecular analyses of early-stage TGCT patients.
- Analysis of molecular alterations in cisplatin-resistant TGCT cases.
- Characterization of the role of epigenetics in TGCT development and prognosis.
Main Results:
- Adult TGCTs exhibit frequent chromosomal anomalies and low somatic mutation rates, with common isochromosome 12p gain.
- Mutations in genes like KIT and KRAS are confirmed, alongside novel mutations.
- Cisplatin-resistant cases show high TP53-MDM2 axis alterations and actionable targets in PI3 kinase and MAPK pathways.
Conclusions:
- Further molecular characterization of TGCT can help avoid overtreatment in early-stage disease.
- Identifying molecular targets offers new treatment avenues for cisplatin-resistant TGCT.
- Advanced understanding of TGCT biology supports personalized medicine and novel therapeutic development.
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes